The efficacy of the analgesic GlyT2 inhibitor, ORG25543 , is determined by two connected allosteric sites
Journal of Neurochemistry · 2024
DOI: 10.1111/jnc.16028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2024. Verfasst von Ryan Cantwell Chater und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Glycine Plasma Membrane Transport Proteins, Analgesics, Allosteric Site. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, National Health and Medical Research Council, National Institute for Drug Abuse, USA.
Abstract (Originalsprache)
Glycine Transporter 2 (GlyT2) inhibitors have shown considerable potential as analgesics for the treatment of neuropathic pain but also display considerable side effects. One potential source of side effects is irreversible inhibition. In this study, we have characterized the mechanism of ORG25543 inhibition of GlyT2 by first considering three potential ligand binding sites on GlyT2—the substrate site, the vestibule allosteric site and the lipid allosteric site. The three sites were tested using a combination of molecular dynamics simulations and analysis of the inhibition of glycine transport of a series point mutated GlyT2 using electrophysiological methods. We demonstrate that the lipid allosteric site on GlyT2 is the most likely binding site for ORG25543. We also demonstrate that cholesterol derived from the cell membrane can form specific interactions with inhibitor‐bound transporters to form an allosteric network of regulatory sites. These observations will guide the future design of GlyT2 inhibitors with the objective of minimising on‐target side effects and improving the therapeutic window for the treatment of patients suffering from neuropathic pain. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
- Research School of Chemistry, College of Science, The Australian National University, Canberra, Australian Capital Territory, Australia.
- Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, New York, USA.
ORCID-Profile: Ryan Cantwell Chater, Ada S Quinn, Katie Wilson, Patrick Sutton, Robert J Vandenberg
Förderung
- NIDA NIH HHS
- National Health and Medical Research Council
- National Institute for Drug Abuse, USA
Zitieren
APA
Chater, R. C., Quinn, A. S., Wilson, K., Frangos, Z. J., Sutton, P., Jayakumar, S., Cioffi, C. L., O'Mara, M. L., & Vandenberg, R. J. (2024). The efficacy of the analgesic GlyT2 inhibitor, ORG25543 , is determined by two connected allosteric sites. Journal of Neurochemistry. https://doi.org/10.1111/jnc.16028
Vancouver
Chater RC, Quinn AS, Wilson K, Frangos ZJ, Sutton P, Jayakumar S, et al. The efficacy of the analgesic GlyT2 inhibitor, ORG25543 , is determined by two connected allosteric sites. Journal of Neurochemistry. 2024. doi:10.1111/jnc.16028
BibTeX
@article{Chater2024,
author = {Chater, Ryan Cantwell and Quinn, Ada S and Wilson, Katie and Frangos, Zachary J and Sutton, Patrick and Jayakumar, Srinivasan and Cioffi, Christopher L and O'Mara, Megan L and Vandenberg, Robert J},
title = {The efficacy of the analgesic GlyT2 inhibitor, ORG25543 , is determined by two connected allosteric sites},
journal = {Journal of Neurochemistry},
year = {2024},
doi = {10.1111/jnc.16028}
}
EUVIMED